Fonte: Revista Turismo Estudos e Práticas - RTEP/UERN; No. 2 (2020): Geplat: Caderno Suplementar ; 1-9
Palavras-chave:
Resumo: The effect of the metabolic syndrome on the course of prostate cancer (PCa) is increasingly becoming the subject of scientific discussion. However, there are practically no data on the clinical phenotype “prostate cancer + metabolic syndrome” (PCa + MS) in the Kazakh population. The study compared the signs characterizing the aggressiveness of prostate cancer in the Kazakh population between two clinical phenotypes: PCa + MS - the main group and PCa-MS - the comparison group. Potential participants of the study were of Kazakh patients with PCa who visited a urologist in oncological centers of Kazakhstan in the second half of 2018. After written consent, data were collected using specially designed questionnaires and a medical card. The differences between the two phenotypes were evaluated using x2 test, Student's test, Mann-Whitney and the relative risk was evaluated. The participants with the PCa + MS phenotype when making diagnosis of PCa were 4.47 years younger (p <0.05), more often had PSA level above 20 ng / ml (41.8% vs 40.9%, p <0. 05), more often revealed metastatic form of the disease (57.69% vs 38.84%, p <0.05). A year after radical prostatectomy, patients of the main group were more likely to have a biochemical recurrence of the disease: 4.8% vs 3.7% (relative risk 1.29). The study showed statistically significant aggressiveness of PCa+MS in the Kazakh population. At the same time, the study performed is not a direct evidence, but the results indicate the need to consider the inclusion of the clinical phenotype in PCa definition of prostate cancer for the Kazakh population, which will provide a more active position when monitoring patients with metabolic syndrome.
